Royalty Pharma plc Class A Ordinary Shares vs Consumer Staples Select Sector SPDR Fund — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B), while Consumer Staples Select Sector SPDR Fund trades at $83.24 (market cap $13.50B). The key difference: Royalty Pharma plc Class A Ordinary Shares is the larger of the two by market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| RPRX | XLP | |
|---|---|---|
Market Cap | $25.27B | $13.50B |
Volume | 3,671,183 | 14,599,953 |
Sector | Health | — |
52-Week High | $63.96 | $90.00 |
52-Week Low | $35.44 | $75.61 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.
The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →